Alphatec’s post-earnings selloff masks a high-growth, software-enabled spine surgery platform with powerful consumable economics, but leverage, EOS execution, and patent litigation keep the risk profile elevated.
Overview
Alphatec is a pure-play spine medtech company focused on transforming spinal surgery into integrated, reproducible workflows. About 93% of revenue comes from surgical products—implants, instruments, access systems, and biologics—while EOS imaging adds capital equipment, software, and planning capabilities. Its U.S.-centric business is expanding internationally, especially in Japan. Hospitals and surgeons adopt Alphatec for proceduralized systems that combine implants, neuromonitoring, imaging, and AI-driven planning to reduce variability, shorten operating time, improve outcomes, and create sticky consumable revenue.